All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.

Biological Description

Description: BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.

Targets&IC50: IκBα phosphorylation:10 μM

Kinase Assay: UBE1 (0.17 μM) in 22.5 μL of 20 mM Hepes, pH 7.5, containing 10 μM ubiquitin is incubated for 45 min at 21°C with 1 μL of DMSO or 1 μL of BAY 11-7082 in DMSO. A 2.5 μL solution of 10 mM magnesium acetate and 0.2 mM ATP is added, incubated for 10 min at 30°C, and the reactions are terminated by the addition of 2.5 μL of 10% (w/v) SDS and heating for 6 min at 75°C. The samples are subjected to SDS/PAGE in the absence of any thiol. The gels are stained for 1 h with Coomassie Instant Blue and destained by washing with water. The loading of ubiquitin to E2 conjugating enzymes is carried out in an identical manner, except that UBE1 (0.17 μM) is mixed with Ubc13 (2.4 μM) or UbcH7 (2.9 μM) prior to incubation with BAY 11-7082.

Cell Research: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.(Only for Reference)

Chemical Properties

Molecular Weight: 207.25

Formula: C10H9NO2S

CAS No.: 19542-67-7

Storage & Solubility Information

Storage

Powder: -20°C for 3 years

In solvent: -80°C for 2 years

Solubility Information

Ethanol: 5.2 mg/mL (25 mM)

DMSO: 20.7 mg/mL (100 mM)

( < 1 mg/ml refers to the product slightly soluble or insoluble )

Catalog #: T1902

Please email us at cs@medikonia.com for any enquiry. To place an order, please include the catalog number(s) of the product(s) in the email.

References and Literature

1. Melisi D, et al. Expert Opin Ther Targets, 2007, 11(2), 133-144.

2. Gastonguay A, et al. Cancer Biol Ther, 2012, 13(8), 647-656.

3. Miwatashi S, et al. J Med Chem, 2005, 48(19), 5966-5979.

4. Mori N, et al. Blood, 2002, 100(5), 1828-1834.

5. Goffi F, et al. Neurosci Lett, 2005, 377(3), 147-151.

6. Jun Jacob Hu, et al. Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D. The Preprint Server For Biology, 2018,Jul. 10.

7. Shen S C, He F, Cheng C, et al. Uric acid aggravates myocardial ischemia–reperfusion injury via ROS/NLRP3 pyroptosis pathway[J]. Biomedicine & Pharmacotherapy . 2020, 133: 110990.

8. Yu Y, Li Z, Guo R, et al. Ononin, sec-O-β-D-glucosylhamaudol and astragaloside I: antiviral lead compounds identified via high throughput screening and biological validation from traditional Chinese medicine Zhongjing formulary[J]. Pharmacological Research. 2019 May 11;145:104248.

10. Gao J, Wang Y, Zhang W, et al. C20orf27 Promotes Cell Growth and Proliferation of Colorectal Cancer via the TGFβR-TAK1-NFĸB Pathway[J]. Cancers. 2020, 12(2): 336.